Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of different anticoagulation strategies in recurrent spontaneous abortion with antiphospholipid antibodies
ChiCTR2000034205Phase 4Not yet recruiting
- Sponsor
- Qingdao Jinhua Maternity Hospital
- Start
- Jun 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of low molecular weight heparin calcium and fondaparinux in recurrent miscarriage (RPL) and antiphospholipid syndrome (APS) (3 arms), sponsored by Qingdao Jinhua Maternity Hospital. Primary endpoints: Live birth rate and Safety during pregnancy. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
low molecular weight heparin calciumfondaparinux
03
Conditions
recurrent miscarriage (RPL)antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on ChiCTR2000034205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034205.